Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

New Gene Therapies Have Hit The Market; Drug Makers Discuss Initial Launch Trends

Aug 11 2023

• By Jessica Merrill

• Source: Shutterstock

Related Content

BioMarin Hopes A Single Warranty Will Make Gene Therapy Reimbursement Simpler

Jan 10 2023

Its Gene Therapy Roctavian Finally Approved With $2.9m Price, BioMarin Aims To Prove Doubters Wrong

Jun 30 2023

BioMarin’s $1m Gene Therapy Roctavian Hits Payer Problems In Germany

Apr 28 2023

A Momentous Day For DMD: Sarepta’s Elevidys Is First Gene Therapy Approved

Jun 23 2023

Related Companies

BioMarin Pharmaceutical Inc.

Sarepta Therapeutics, Inc.

Bluebird Bio

Additional Topics

Gene Therapy Launches Market Access Commercial BioPharmaceutical

More from Gene Therapies

More from Advanced Therapies

Twitter feed RSS feed RSS feed

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.